InvestorsHub Logo
Followers 660
Posts 83828
Boards Moderated 0
Alias Born 05/25/2008

Re: sal32647 post# 110

Friday, 05/26/2023 8:22:08 PM

Friday, May 26, 2023 8:22:08 PM

Post# of 230
The gross proceeds to the Company from the registered direct offering and the concurrent private placement were approximately $1.8 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds for general corporate purposes, which includes, without limitation, ongoing research and pre-clinical studies, clinical trials, the development of new biological and pharmaceutical technologies, investing in or acquiring companies that are synergistic with or complementary to our technologies, licensing activities related to our current and future product candidates, and to the development of emerging technologies, investing in or acquiring companies that are developing emerging technologies, licensing activities, or the acquisition of other businesses and working capital.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DRMA News